BiOptic Awarded U.S. Patent for “Glycan Profiling Utilizing Capillary Electrophoresis”
2025-11-24
In the field of glycoscience and glycobiology, Academician Chi-Huey Wong has long been one of Taiwan's most influential scientific leaders. His groundbreaking research in glycan chemistry, biomedical applications, and vaccine strategies has not only elevated Taiwan's presence on the global stage, but has also earned him recognition from major international media as a strong contender for the Nobel Prize in Chemistry.
BiOptic Qampmini Thermal Cycler has received Class I Medical Device Certification!
2023-12-21
BiOptic Qampmini Thermal Cycler has received Class I Medical Device Certification of Taiwan Food and Drug Administration (TFDA)
Qampmini has been listed as a Class I Medical Device in the U.S. Food and Drug Administration (FDA) since JAN 2023, and is now granted by the Taiwan Food and Drug Administration (TFDA). It can be sold as a medical device to demand institutions from the date of grant.
【Congratulations!】BiOptic has received an India invention patent
2023-12-18
BiOptic has received a new invention patent for the Qsep400 Bio-Fragment Analyzer and 4-channel cartridge from India!The biopharmaceutical industry in India is a very important emerging market in the globe. Local R&D investment in the biopharmaceutical industry accounts for 60% of the total investment. Plus, it has become the world's largest vaccine producer and the world's largest manufacturer of generic drugs!
Congratulations! BiOptic’s core products have successfully registered and listed in FDA!
2023-02-22
BiOptic has recently registered and listed the core products and related consumables in the USA FDA Class I category. Items including Qsep Series Bio-Fragment Analyzers, Qampmini Thermal Cycler and multiple cartridges ,etc. In the future, the above mentioned core products can be sold as medical equipment in the United States, which will expand our business scope in the US market.